PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
May 28, 2020
SOUTH PLAINFIELD, N.J. , May 28, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in the series will discuss its Bio-e platform on Friday, June 5
Additional Formats
May 27, 2020
SOUTH PLAINFIELD, N.J. , May 27, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the
Additional Formats
May 26, 2020
SOUTH PLAINFIELD, N.J. , May 26, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 nd at 1:00 p.m. ET . The presentation will be webcast live on the Events and
Additional Formats
May 15, 2020
SOUTH PLAINFIELD, N.J. , May 15, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 11, 2020 it approved non-statutory stock options to purchase an aggregate of 50,025 shares of its common stock and 4,470 restricted stock units ("RSUs"), each representing the
Additional Formats
May 06, 2020
- Acquisition diversifies and strengthens PTC Therapeutics' rare disorders portfolio - - Compelling Phase 3 ready asset to potentially address unmet need in PKU - SOUTH PLAINFIELD, N.J. , May 6, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an
Additional Formats
May 05, 2020
SOUTH PLAINFIELD, N.J. , May 5, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present in a virtual format at the following conferences: 2020 BofA Securities Health Care Conference Tuesday, May 12 th at 3:40 p.m.
Additional Formats
Apr 30, 2020
- Risdiplam demonstrated clinically meaningful and statistically significant results across broadest population of spinal muscular atrophy (SMA) patients studied to date; PDUFA date August 24, 2020 - - PTC provides an update on clinical and regulatory programs - - First quarter 2020 total revenues
Additional Formats
Apr 28, 2020
- Part 2 of pivotal study met its primary endpoint by demonstrating unsupported sitting in infants aged 1-7 months with type 1 SMA after 12 months of treatment - - Meaningful benefit observed in dose-finding Part 1 confirmed - - PDUFA expected August 24, 2020 - SOUTH PLAINFIELD, N.J.
Additional Formats
Apr 22, 2020
SOUTH PLAINFIELD, N.J. , April 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 17, 2020 it approved non-statutory stock options to purchase an aggregate of 151,850 shares of its common stock and 6,260 restricted stock units ("RSUs"), each representing
Additional Formats
Apr 17, 2020
SOUTH PLAINFIELD, N.J. , April 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Matthew Klein , M.D., to Chief Development Officer and Eric Pauwels to Chief Business Officer. Dr. Klein will be responsible for the development of our clinical stage
Additional Formats